MoonLake Immunotherapeutics Receives Regulatory Greenlights for Phase 3 Program of Sonelokimab in PsA
MoonLake Immunotherapeutics received positive feedback from the U.S. Food and Drug Administration (FDA) and the E.U. European Medicines Agency (EMA) on its Phase 3 Program for the nanobody sonelokimab in Psoriatic Arthritis (PsA). Sonelokimab (M1095) is an investigational ~40 kDa humanized nanobody consisting of three VHH domains covalently linked by flexible glycine-serine spacers. With two domains, […]